EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 21 filers reported holding EVOKE PHARMA INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $21,000 | -32.3% | 42,793 | -22.7% | 0.00% | -33.3% |
| Q4 2021 | $31,000 | +24.0% | 55,336 | +192.5% | 0.00% | +50.0% |
| Q3 2021 | $25,000 | -46.8% | 18,918 | +3.2% | 0.00% | -60.0% |
| Q4 2020 | $47,000 | -32.9% | 18,335 | -57.6% | 0.01% | -28.6% |
| Q4 2019 | $70,000 | +4.5% | 43,210 | -59.8% | 0.01% | +75.0% |
| Q2 2019 | $67,000 | -43.2% | 107,438 | +36.4% | 0.00% | -42.9% |
| Q1 2019 | $118,000 | +47.5% | 78,787 | +195.2% | 0.01% | +40.0% |
| Q3 2018 | $80,000 | +105.1% | 26,686 | +70.0% | 0.01% | +150.0% |
| Q2 2018 | $39,000 | -18.8% | 15,695 | -26.9% | 0.00% | -33.3% |
| Q4 2017 | $48,000 | -63.6% | 21,457 | -45.7% | 0.00% | -57.1% |
| Q3 2017 | $132,000 | – | 39,489 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |